Progressive Supranuclear Palsy (Central Nervous System) - Drugs in Development, 2021

November 2021 | 136 pages | ID: P2C2E62E60B4EN
Global Markets Direct

Abstracts

Progressive Supranuclear Palsy (Central Nervous System) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2021, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.

Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 8, 11 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Progressive Supranuclear Palsy - Overview
Progressive Supranuclear Palsy - Therapeutics Development
Progressive Supranuclear Palsy - Therapeutics Assessment
Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development
Progressive Supranuclear Palsy - Drug Profiles
Progressive Supranuclear Palsy - Dormant Projects
Progressive Supranuclear Palsy - Discontinued Products
Progressive Supranuclear Palsy - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Progressive Supranuclear Palsy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Progressive Supranuclear Palsy - Pipeline by AbbVie Inc, 2021
Progressive Supranuclear Palsy - Pipeline by Allyx Therapeutics Inc, 2021
Progressive Supranuclear Palsy - Pipeline by Alterity Therapeutics Ltd, 2021
Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, 2021
Progressive Supranuclear Palsy - Pipeline by Anhorn Medicines Co Ltd, 2021
Progressive Supranuclear Palsy - Pipeline by Aprinoia Therapeutics Inc, 2021
Progressive Supranuclear Palsy - Pipeline by Arvinas Inc, 2021
Progressive Supranuclear Palsy - Pipeline by Asahi Kasei Pharma Corp, 2021
Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, 2021
Progressive Supranuclear Palsy - Pipeline by AZTherapies Inc, 2021
Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, 2021
Progressive Supranuclear Palsy - Pipeline by EmeraMed Ltd, 2021
Progressive Supranuclear Palsy - Pipeline by Merck & Co Inc, 2021
Progressive Supranuclear Palsy - Pipeline by NeuroTau Inc, 2021
Progressive Supranuclear Palsy - Pipeline by New Amsterdam Sciences Inc, 2021
Progressive Supranuclear Palsy - Pipeline by Novartis AG, 2021
Progressive Supranuclear Palsy - Pipeline by Pinteon Therapeutics Inc, 2021
Progressive Supranuclear Palsy - Pipeline by Prothena Corp Plc, 2021
Progressive Supranuclear Palsy - Pipeline by Retrotope Inc, 2021
Progressive Supranuclear Palsy - Pipeline by TauC3 Biologics Ltd, 2021
Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, 2021
Progressive Supranuclear Palsy - Pipeline by Transposon Therapeutics Inc, 2021
Progressive Supranuclear Palsy - Pipeline by UCB SA, 2021
Progressive Supranuclear Palsy - Pipeline by Unity Biotechnology Inc, 2021
Progressive Supranuclear Palsy - Pipeline by Vaxxinity Inc, 2021
Progressive Supranuclear Palsy - Pipeline by Velacor Therapeutics Pty Ltd, 2021
Progressive Supranuclear Palsy - Pipeline by Verge Genomics Inc, 2021
Progressive Supranuclear Palsy - Pipeline by Voyager Therapeutics Inc, 2021
Progressive Supranuclear Palsy - Dormant Projects, 2021
Progressive Supranuclear Palsy - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Progressive Supranuclear Palsy, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021